|  |  |  |  |
| --- | --- | --- | --- |
| Variable | Alive without AI, N = 4621 | AI deaths, N = 61 | p-value2 |
| Age at enrolment, median (IQR) (years) | 36 (31, 43) | 41 (33, 46) | 0.5 |
| Gender, n(%) |  |  | >0.9 |
| Female | 234 (50.8%) | 3 (50.0%) |  |
| Male | 227 (49.2%) | 3 (50.0%) |  |
| Ethnicity, n(%) |  |  | 0.6 |
| Black African | 355 (76.8%) | 4 (66.7%) |  |
| Other | 107 (23.2%) | 2 (33.3%) |  |
| Duration of current illness, median (IQR) (days) | 14 (10, 21) | 14 (11, 14) | 0.3 |
| Weight loss | 379 (86.1%) | 4 (66.7%) | 0.2 |
| Viral load (log10 Copies/mL) | 10.4 (6.3, 12.3) | NA (NA, NA) | |
| Tuberculosis | 391 (84.6%) | 5 (83.3%) | >0.9 |
| Cryptococcus neoformans | 17 (3.7%) | 3 (50.0%) | 0.001 |
| Pneumonia | 52 (11.3%) | 0 (0.0%) | >0.9 |
| Staph aureus | 0 (0.0%) | 0 (0.0%) |  |
| Kaposis sarcoma | 5 (1.1%) | 0 (0.0%) | >0.9 |
| Cytomegalovirus | 0 (0.0%) | 0 (0.0%) |  |
| HSV | 6 (1.3%) | 0 (0.0%) | >0.9 |
| HepB | 16 (3.5%) | 1 (16.7%) | 0.2 |
| Candida | 29 (6.3%) | 0 (0.0%) | >0.9 |
| GE/c diff | 23 (5.0%) | 0 (0.0%) | >0.9 |
| Parvo B19 | 0 (0.0%) | 0 (0.0%) |  |
| Syphilis | 14 (3.0%) | 0 (0.0%) | >0.9 |
| B menigitis | 5 (1.1%) | 0 (0.0%) | >0.9 |
| UTI / Leptospirosis | 6 (1.3%) | 0 (0.0%) | >0.9 |
| PCP | 3 (0.6%) | 0 (0.0%) | >0.9 |
| COVID-19 | 2 (0.4%) | 0 (0.0%) | >0.9 |
| Neurocysticercosis | 2 (0.4%) | 0 (0.0%) | >0.9 |
| Total CD4 count | 34 (15, 65) | 30 (16, 45) | >0.9 |
| White cell count X109 | 5.6 (3.8, 8.2) | 8.3 (4.3, 27.5) | 0.3 |
| Sodium mmol/L | 133.0 (130.0, 137.0) | 136.5 (133.3, 139.0) | |
| Potassium mmol/L | 4.10 (3.70, 4.60) | 3.70 (3.37, 3.88) | |
| Haemoglobin g/dL | 8.70 (7.40, 10.40) | 9.60 (8.25, 10.95) | 0.2 |
| BP (systolic) | 112 (103, 127) | 128 (122, 130) | 0.038 |
| BP (diastolic) | 70 (60, 77) | 74 (65, 78) | 0.5 |
| Heart rate | 91 (78, 109) | 87 (72, 98) | 0.14 |
| Hypotension | 39 (8.9%) | 0 (0.0%) | 0.5 |
| Weakness | 368 (84.0%) | 4 (66.7%) | 0.4 |
| Tiredness | 370 (84.1%) | 6 (100.0%) | >0.9 |
| Poor appetite | 323 (74.3%) | 6 (100.0%) | 0.3 |
| Increased pigmentation of the skin | 211 (49.2%) | 2 (40.0%) | 0.6 |
| Nausea | 226 (51.6%) | 5 (83.3%) | 0.3 |
| Vomiting | 122 (27.9%) | 2 (33.3%) | >0.9 |
| Liking for salt | 224 (51.4%) | 4 (66.7%) | 0.2 |
| Hypoglycaemia | 9 (2.1%) | 0 (0.0%) | 0.7 |
| Loss of consciousness | 5 (1.1%) | 0 (0.0%) | 0.7 |
| Diarrhoea | 186 (42.9%) | 1 (16.7%) | >0.9 |
| Dizziness | 202 (46.2%) | 3 (50.0%) | >0.9 |
| Shock | 3 (0.7%) | 0 (0.0%) | 0.2 |
| Anorexia | 199 (45.5%) | 2 (33.3%) | >0.9 |
| Loss of axillary and pubic hair, if female |  |  | >0.9 |
| No | 147 (33.0%) | 2 (33.3%) | 0.7 |
| Not applicable | 222 (49.9%) | 3 (50.0%) | >0.9 |
| Yes | 76 (17.1%) | 1 (16.7%) |  |
| Any postural drop in blood pressure | 17 (3.9%) | 0 (0.0%) |  |
| Presence of anaemia | 252 (57.9%) | 3 (50.0%) |  |
| ART exposure | 175 (37.9%) | 1 (16.7%) | >0.9 |
| Kidney medication | 37 (8.0%) | 1 (16.7%) | 0.7 |
| incremental cortisol | 286 (195, 383) | 41 (19, 93) | 0.4 |

1Median (IQR); n (%); 2Wilcoxon rank sum test; Fisher’s exact test